Is NCT07645248 recruiting in Owensboro, KY?

Yes, NCT07645248 is currently enrolling participants at its Owensboro, KY location. This asthma clinical trial is accepting qualified participants.

How do I join the asthma clinical trial in Owensboro?

To join this clinical trial in Owensboro, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Owensboro clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Asthma Clinical Trial in Owensboro, KY: HFA-152a (Phase 3)

Who Can Participate

Inclusion Criteria

Participant must be aged greater than equal to (\>=)18 years at the time of signing the informed consent.

Participants with asthma for \>= 6 months, defined as:

Documented history of asthma, as defined by Global Initiative for Asthma (GINA)

Receiving one of following asthma treatments for at least 12 weeks prior to the screening visit and which is anticipated to remain stable for the duration of the study:

Short-Acting beta2-Adrenoreceptor Agonists (SABA) as needed (prn) only

Inhaled corticosteroid (ICS)/SABA prn only

SABA prn plus ICS prn

SABA prn plus ICS maintenance

ICS/SABA prn plus ICS maintenance

SABA prn plus ICS/ Long-acting beta agonist (LABA) maintenance

ICS/SABA prn plus ICS/LABA maintenance

SABA prn plus ICS/ Long-acting muscarinic antagonist (LAMA)/LABA maintenance (open or closed triple therapy)

ICS/Formoterol combination therapy as reliever therapy

ICS/Formoterol combination therapy as maintenance therapy plus ICS/Formoterol combination as reliever therapy.

Leukotriene receptor antagonist (LTRA) as add-on any of the above is permitted

Xanthines as add-on to any of the above permitted

Biological therapies indicated for the treatment of asthma as add-on to any of the above are permitted (for example, but not limited to, mepolizumab, dupilumab, tezepelumab).

Participants with severity of disease:

Baseline pre-bronchodilator Forced expiratory volume in 1 second (FEV1) \>=50 percent (%) of predicted at screening.

Asthma Control Status

Asthma Control Questionnaire (ACQ)-6 score less than (\<) 1.5 at screening (and randomization).

Asthma that has remained stable with no severe exacerbations within the last 3 months.

Participants who are current non-smokers, who have not used any inhaled tobacco or vaping products within 12 months of the start of the study, and with a total pack year history of less than equal to (\<=)10 pack. The use of inhaled marijuana, even with a valid prescription, is prohibited within 12 months prior to study start.

Participants who demonstrate ability to use pressurized MDI device in a satisfactory and repeatable manner, as judged visually by the investigator or designee.

Male and female participants are eligible. A female participant is eligible to participate if they are not pregnant or breastfeeding, and one of the following conditions applies:

Is a Participant of nonchildbearing potential (PONCBP) or

Is a Participant of childbearing potential (POCBP) and using a contraceptive method that is highly effective, with a failure rate of \<1%, 30 days prior to and during the study intervention period and for at least 24 hours after the last dose of study intervention. - A POCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours before the first dose of study intervention in each Treatment Period.

Adults capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the Informed consent form (ICF).

Exclusion Criteria

Participants with a history of life-threatening asthma.

Participants with other significant pulmonary diseases, including (but not limited to): pneumothorax, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic bronchitis, emphysema, chronic obstructive pulmonary disease, tuberculosis, or other significant respiratory abnormalities other than asthma.

Respiratory Infection: Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 4 weeks of screening.

Participants with severe asthma exacerbation: Defined as any asthma exacerbation requiring \>=3 days systemic corticosteroids or that resulted in overnight hospitalization or Emergency Department visit requiring additional treatment for asthma within the 3 months prior to screening.

Participants with Other concurrent Diseases/Abnormalities: A participant has any clinically significant, uncontrolled condition or disease state that, in the opinion of the investigator, would put the safety of the participant at risk through study participation or would confound the interpretation of the study results.

Participants with current use of cholinesterase inhibitor medication (e.g. for myasthenia gravis).

Participants with any other prescription or over the counter medication which would significantly affect the course of asthma, or that could interact with sympathomimetic amines.

Participants with Drug or Excipient Allergy: Known or suspected sensitivity to the constituents of salbutamol MDI (e.g. HFA-134a, Oleic acid etc.).

Participants with exposure to more than four new chemical entities within 12 months prior to the first dosing day or participation in a clinical study within 30 days of study start, or 5 half-lives of study drug if that is longer.

Participants with a known or suspected history of alcohol or drug abuse.

Any planned or anticipated changes in asthma medications during the study period.

Any planned environmental changes (e.g. employment changes, travel) which, in the Investigator's opinion, could lead to e.g. increased allergen exposure.

12-Lead ECG abnormality: Significant abnormality in the 12-lead ECG performed at screening.

Alanine transaminase (ALT) \>2 times Upper limit of normal (ULN).

Total bilirubin \>1.5 times ULN; For participants with Gilbert's syndrome can be included with total bilirubin \>1.5 times ULN if direct bilirubin is \<=1.5 times ULN.

Participants with Cirrhosis or current unstable liver or biliary disease.

Participants with QTc \>480 milliseconds (msec).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Owensboro?

Yes, this clinical trial (NCT07645248) has an active research site in Owensboro, KY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Asthma Treatment Options in Owensboro, KY

If you're searching for asthma treatment options in Owensboro, KY, this clinical trial (NCT07645248) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Owensboro research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced asthma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all asthma clinical trials near you to find additional studies recruiting in your area.

Asthma Clinical Trial in Owensboro, KY

Expert Care in Owensboro

IRB Approved

No-Cost Care

Apply for This Owensboro Location

Why Participate?

Simple Process

About This Asthma Study in Owensboro